Cargando…

New immunotherapeutic paradigms for castration-resistant prostate cancer

Detalles Bibliográficos
Autor principal:	Galluzzi, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2013
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178378/ https://www.ncbi.nlm.nih.gov/pubmed/28090392 http://dx.doi.org/10.4161/onci.26084

Ejemplares similares

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions
por: Yu, Evan Y, et al.
Publicado: (2014)

New ideas in preventing castration-resistant prostate cancer
por: Tsai, Yuan-Chin, et al.
Publicado: (2017)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
por: Yang, Hanny, et al.
Publicado: (2022)

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer
por: Armstrong, Cameron M., et al.
Publicado: (2016)

A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer
por: Parent, Ephraim E., et al.
Publicado: (2022)

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021)

New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer
por: Lin, Ching-Yu, et al.
Publicado: (2020)

New Therapeutics to Treat Castrate-Resistant Prostate Cancer
por: Acar, Ömer, et al.
Publicado: (2013)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

Definition of Castrate Resistant Prostate Cancer: New Insights
por: Morote, Juan, et al.
Publicado: (2022)

The changing landscape of hormonal therapy in castration-resistant prostate cancer
por: Dongre, Amol, et al.
Publicado: (2012)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
por: Heck, Matthias M., et al.
Publicado: (2013)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
por: Heidegger, Isabel, et al.
Publicado: (2018)

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
por: Teo, Min Yuen, et al.
Publicado: (2018)

Insights into the prognostic potential of total alkaline phosphatase in metastatic castration-resistant prostate cancer treated with radium-223
por: Viani, Gustavo
Publicado: (2023)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance
por: Huang, Phoebe A., et al.
Publicado: (2018)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Ailanthone: a new potential drug for castration-resistant prostate cancer
por: Peng, Shihong, et al.
Publicado: (2017)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

National Consensus on Non-metastatic Castration-Resistant Prostate Cancer: more than just a snapshot
por: Reis, Leonardo Oliveira, et al.
Publicado: (2021)

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

Peptide-Based Immunotherapeutics and Vaccines
por: Reche, Pedro A., et al.
Publicado: (2014)

Immunotherapeutic Targeting in Autoimmune Diseases
por: Janikashvili, Nona, et al.
Publicado: (2016)

Integrated network model provides new insights into castration-resistant prostate cancer
por: Hu, Yanling, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s9ndgh7ht219g394hs1fmpj9sv